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neuroscience is the potential for stem cells
to treat brain damage. Cell-based strate-
gies are of particular interest in neurolog-
ical conditions because mature brains
have limited capacity for self-repair. It is
often argued that stem cells might be
used to replace lost neurons and restore
function (Lindvall et al., 2004). Prior to
clinical trials, safety and efficacy must
be demonstrated in animal models.
Indeed, a recent review strongly suggests
that preclinical and clinical trial proce-
dures and outcome measures, including
behavioral assessments, must be closely
aligned and sophisticated (Ginsberg,
2008). Unfortunately, a lack of transla-
tional success has been observed in
stroke neuroprotection trials conducted
thus far, and this experience should serve
to caution that histological benefits in
animals are not a sufficient reason to
move to the clinic carelessly.
Several committees (STAIR, 1999; Dir-
nagl, 2006; STEPS, 2009) have proposed
a design framework aimed to improve
the quality of preclinical stroke studies,
and although specific behavioral tests
were not indicated, the groups clearly
recommend that behavioral outcomes
be included. Below we list studies from
the literature, 2001 onward, that assessed
functional outcome after cell-based
therapy in focal cerebral ischemia models.
The results suggest issues to be consid-
ered when selecting cell-based behavioral
assessments, not only for stroke research
but also for the broader field of regenera-
tive medicine.
Seventy studies that used behavioral
outcome measures to assess cell-based
treatment for focal cerebral ischemia
in rodents were included for analysis
(Table S1 available online) on the basis
of a PubMed search (see Supplemental
Data). The vast majority of these testswere carried out in rats and used a variety
of stroke models including transient
middle cerebral artery occlusion (tMCAO)
and permanent MCAO (pMCAO). These
insults were treated by intravenous (47%),
intracerebral (41%), or intra-arterial (10%)
administration of cells, usually 24 hr or
less after occlusion. Follow-up times
varied from 3 days to 1 year. The origins
of cell preparations were human (46%),
rat (41%), or mouse (13%).
Multiple tests were used in 48 of these
studies, with the most prevalent being
versions of the NSS, the adhesive-
removal test, and rotarod (Table 1). Less
frequently used were the cylinder test,
treadmill, ledged tapered beam, and
Montoya’s staircase test. Simple versions
of the Morris water maze and passive
avoidance memory tests were also
included. The rationale for the choice of
specific tests was not indicated, but we
speculate that the time required to
conduct each test may have been
a contributing factor (Table S2).
The frequency with which a positive
treatment effect was associated with
a particular behavioral test is displayed
in Table 1. The treadmill, NSS, rotarod,
adhesive-removal latency, and limb-
placing tests were strongly associated
with positive treatment effects. The water
maze or passive avoidance tests also
produced a high frequency of positive
results. In contrast, the cylinder, tapered
beam, and Montoya’s staircase tests, all
of which were relatively underrepresented
in the study cohort, showed treatment
effects in relatively few cases. In most
instances, we could not establish whether
behavioral testing was carried out blind to
the treatment condition. Blinded assess-
ment of outcome is much more likely to
yield neutral results (Sena et al., 2007).
Despite the point that the studies were
designed to test cell-mediated injuryrepair, only 50% of the papers reported
cell-survival quantification, and 40%
did not report cell phenotypes in vivo
(Table S1). Cell survival was minimal in
most studies, and variable neuronal differ-
entiation was reported; thus it is difficult to
correlate the results of the behavioral
tests with transplanted cell engraftment.
In addition, although the 70 records
screened comprise a presumably repre-
sentative, although not all-embracing,
snapshot in the field, one should note
that negative studies are less likely to be
published. Also, some biotech companies
withhold large amounts of data (Sena
et al., 2007).
Overall, our analysis has thus far re-
vealed that some behavioral tests, often
the more frequently reported assays, are
more likely to yield positive treatment
effects. However, it must be acknowl-
edged that treatment-induced behavioral
improvement may be due to enhanced
compensatory learning (Schallert, 2006;
Kleim, 2009). To illustrate, with a stroke-
like behavior as an example, if one hind-
limb of a neurologically intact animal
is peripherally incapacitated, treadmill
walking and rotarod performance are
compromised severely at first but gradu-
ally improve because the animal learns
novel ways to rely on the other limbs
and on tail deviation for balance and
movement. A cell-based treatment that
enhances motivation, motor learning, or
memory might more rapidly improve
quality of gait, capacity to remain on
a rotarod, or other motor functions.
Although this type of restoration of func-
tion could be helpful clinically after
a stroke, the improvement presumably
would be modest compared to that prom-
ised by optimally effective tissue replace-
ment. Forelimb use asymmetry during
cylinder exploration and ledged beam
walking are not affected by repeated
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Behavioral Test Assessment of Frequency Used
Positive Treatment
Effects
mNSS motor and sensory functions, balance and reflexes 29/70 (41%) 28/29 (97%)
Adhesive tape removal forelimb sensory asymmetry 25/70 (36%) 24/25 (96%)
Rotarod coordination, balance, and gross motor functions 18/70 (26%) 17/18 (94%)
Limb-placing responses to tactile and proprioceptive stimulation 11/70 (16%) 9/11 (82%)
Cylinder spontaneous use of forelimbs 8/70 (11%) 4/8 (50%)
Treadmill motor functions, gait 5/70 (7%) 5/5 (100%)
Tapered beam-walking hindlimb functions 3/70 (4%) 0/3 (0%)
Montoya’s staircase skilled forelimb use 1/70 (1%) 0/1 (0%)
Water maze, passive avoidance cognitive functions 14/70 (20%) 11/14 (79%)
Others (e.g., spontaneous activity,
apomorphine/amphetamine-induced rotation)
20/70 (29%)testing, suggesting that learned compen-
satory movements might be less of
a factor when using these assays.
Indeed, cell-based treatments generally
showed little efficacy with these tests.
Thus, it is challenging to rule out that
positive effects of cell-based treatments
are primarily mediated by events other
than cell substitution, such as treat-
ment-enhanced neuroplasticity associ-
ated with experience-related compensa-
tory strategies.
We encourage researchers aiming to
extend animal studies of cell-based treat-
ments for stroke, or indeed for other
injuries, into clinical trials to ensure that
their models are carefully vetted with
multiple behavioral tests that are blindly
carried out long-term, with versus without
rehabilitation, and include at least two
tests that are minimally influenced by
practice so that the potential for false-
positive outcomes could be avoided.
Kinematic analysis of movement quality
should be used for unmasking deficits
that might otherwise go undetected after
repeated testing. Tests for fine digit
control and advanced cognitive tests140 Cell Stem Cell 5, August 7, 2009 ª2009should be included. Cell-based treat-
ments should continue to work long-
term and in multiple stroke models that
otherwise produce lasting deficits in
untreated stroke animals. Cell survival
and phenotypes should be quantified
after behavioral follow up. It should be
noted that for some tests used in neural
deficit assessment, the behavioral
outcome does not correlate well with the
degree of brain injury. If the test cannot
even distinguish among differences in
infarct size, then it is less likely to detect
improved brain integrity from cell treat-
ment. Ideally, although such action is diffi-
cult, a positive treatment effect should be
reversed if the cells are removed or inacti-
vated. Otherwise, the treatment cannot
confidently be viewed as a cell-replace-
ment therapy.
In conclusion, animal research remains
an important tool in assessing safety
and efficacy of cell-based therapies.
Further advances in behavioral assess-
ment should improve the chances for
successful clinical trials, and the experi-
ence with neuroprotection strategies
should serve as an enlightening illustra-Elsevier Inc.tion for consideration during study design
for other disease applications.
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